Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Vectura CFO Sanguine Despite Flutiform Phase III COPD Trial Miss

Executive Summary

Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.

Advertisement

Related Content

Q&A: Vectura's Leaders Explain Synergies And Priorities For Merged Company

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register